8-KMaterial AgreementsSecurities & ListingExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Sep 12, 2005)

Filed September 12, 2005For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) has announced a significant strategic partnership with Novartis Pharma AG, marking a pivotal moment for the company. Under a Stock Purchase Agreement, Novartis will acquire approximately 19.9% of Alnylam's outstanding common stock for an aggregate of approximately $58.5 million, at a price of $11.11 per share. This transaction, which will occur in two closings subject to customary conditions like antitrust review, provides Alnylam with substantial capital and validates its RNA interference (RNAi) technology. Beyond the equity investment, Alnylam has entered into a Research Collaboration and License Agreement with Novartis Institutes for BioMedical Research, Inc. (NIBRI). This collaboration focuses on the discovery and development of RNAi-based therapeutics. NIBRI will provide an initial payment of $10 million to Alnylam, with further payments contingent on research and development milestones, clinical development, and sales. This agreement grants NIBRI rights to Alnylam's RNAi technology while ensuring Alnylam retains rights to targets not selected by Novartis, demonstrating a balanced and potentially lucrative partnership.

Key Highlights

  • 1Novartis to acquire 19.9% of Alnylam's common stock for approximately $58.5 million.
  • 2Stock purchase price set at $11.11 per share.
  • 3Transaction structured in two closings, with the first subject to Hart-Scott-Rodino Act approval.
  • 4Investor Rights Agreement grants Novartis registration rights and provides anti-dilution provisions.
  • 5Novartis agrees to a standstill period, limiting its ability to influence Alnylam's management and policies.
  • 6Research Collaboration and License Agreement with NIBRI (Novartis affiliate) focuses on RNAi therapeutics.
  • 7Alnylam to receive an initial $10 million from NIBRI, with potential for milestone and royalty payments.

Frequently Asked Questions

The agreement involves a significant equity investment by Novartis in Alnylam, providing capital to the company. It also establishes a research collaboration to develop RNAi-based therapeutics, leveraging Alnylam's technology and Novartis's research and development capabilities.

Alnylam is set to receive approximately $58.5 million from Novartis for the purchase of its common stock. Additionally, Alnylam will receive an initial payment of $10 million from NIBRI under the collaboration agreement, with further payments tied to performance.

The collaboration focuses on discovering and optimizing RNAi therapeutics. NIBRI will fund research and development, make milestone payments upon achieving specific targets, and pay royalties on future net sales of products derived from the collaboration. The initial term is three years, with potential extensions.

While Novartis is acquiring a significant minority stake and has certain rights under the Investor Rights Agreement, it has agreed to a standstill period for three years, restricting its ability to acquire more shares, participate in tender offers, or seek to control Alnylam's management or policies, subject to exceptions.